Investor Relations

Samsung Biologics is committed to delivering solid financial results and sustainable business leadership through the maintenance of high standards of responsibility and ethics. Effective governance is critical for us to build a collaborative environment between management and employees, fulfill our responsibilities to clients, and create long-term value for shareholders.

Samsung Biologics (207940)
  • 000,000
  • Change 0,000
  • Change % 0.00
  • Previous Close

    000,000

  • Open

    000,000

  • High

    000,000

  • Low

    000,000

  • Volume

    000,000

Latest Quarterly Results | 2023 4Q (October - December)

*Reports will be available shortly after release.

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION